Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical ...

When it comes to lung cancer risk, we usually think first of smoking—and with good reason. But a new study suggests that what’s on your plate might also play a surprising role. Researchers from the ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

In a review of 182 cancer studies, authors failed to report outcome data by sex in 90% of cases, even though men develop ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

A new artificial intelligence (AI) tool could soon help general practitioners (GPs) detect lung cancer in patients up to four ...

AACR's achievement awards and lectureships recognize innovation in basic, translational, clinical, and epidemiological cancer research.

Summit Therapeutics (NASDAQ:SMMT) stock extends gains as lead cancer drug ivonescimab developed with Akeso (AKESF) ...

Northwestern Medicine scientists have uncovered how a testis-specific protein contributes to tumor growth and progression in ...

A report shows a steady decline in cancer-related deaths in the U.S. over the past 20 years, but an increase in diagnoses among women, especially those in racial minority and ethic groups.